The neuromelanin of human substantia nigra: Physiological and pathogenic aspects

Pigment Cell Research

Volumn 17, Issue 6, 2004, Pages 610-617

  Zucca, Fabio A ^a   Giaveri, Giuseppe ^a   Gallorini, Mario ^a   Albertini, Alberto ^a   Toscani, Marco ^a   Pezzoli, Gianni ^b   Lucius, Ralph ^c   Wilms, Henrik ^d   Sulzer, David ^e   Ito, Shosuke ^f   Wakamatsu, Kazumasa ^f   Zecca, Luigi ^a  

^a CNR   (Italy)

^b PARKINSON INSTITUTE   (Italy)

^c UNIVERSITY OF KIEL   (Germany)

^d Campus Kiel   (Germany)

^e NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^f FUJITA HEALTH UNIVERSITY   (Japan)

Author keywords

Aging; Neuromelanin; Parkinson's disease; Substantia nigra

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CHOLESTEROL; COPPER; CYTOKINE; DOPAMINE; FERRITIN; FREE RADICAL; HEAVY METAL; HYDROGEN PEROXIDE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; IRON; LIPID; MELANIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NEUROMELANIN; NEUROTOXIN; NITRIC OXIDE; ORGANIC COMPOUND; PESTICIDE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; TYROSINE; ZINC;

AGING; BIOSYNTHESIS; BRAIN DISEASE; DEGENERATIVE DISEASE; HUMAN; MICROGLIA; NEUROLOGIC DISEASE; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; REVIEW; SUBSTANTIA NIGRA;

AGING; HUMANS; MELANINS; PARKINSON DISEASE; SUBSTANTIA NIGRA;

ANIMALIA;

EID: 9244242006     PISSN: 08935785     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0749.2004.00201.x     Document Type: Review

References (96)

1. Duffy PE, Tennyson VM. Phase and electron microscopic observations of Lewy bodies and melanin granules in the substantia nigra and locus coeruleus in Parkinson's disease. J Neuropthol Exp Neurol 1965;24:398-414
2. Graham DG. On the origin and significance of neuromelanin. Arch Pathol Lab Med 1979;103:359-362
3. Zecca L, Stroppolo A, Gatti A, Tampellini D, Toscani M, Gallorini M, Giaveri G, Arosio P, Santambrogio P, Fariello RG, Karatekin E, Kleinman MH, Turro N, Hornykiewicz O, Zucca FA. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc Natl Acad Sci U S A 2004;101:9843-9848
4. Fenichel GM, Bazelon M. Studies on neuromelanin. II. Melanin in the brainstems of infants and children. Neurology 1968;18:817-820
5. Zecca L, Fariello R, Riederer P, Sulzer D, Gatti A, Tampellini D. The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's disease. FEBS Lett 2002;510:216-220
6. Adler A. Melanin pigment in the central nervous system of vertebrates. J Comp Neurol 1939;70:315-329
7. Marsden CD. Pigmentation in the nucleus substantiae nigrae of mammals. J Anat 1961;95:256-261
8. Cozzi B, Tozzi F. A spectroscopy study of the equine brain melanins. Archo Vet It (Milano) 1985;36:34-40
9. DeMattei M, Levi AC, Fariello RG. Neuromelanic pigment in substantia nigra neurons of rats and dogs. Neurosci Lett 1986;72:37-42
10. Kastner A, Hirsch EC, Lejeune O, Javoy-Agid F, Rascol O, Agid Y. Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? J Neurochem 1992;59:1080-1089
11. Gibb WR. Melanin, tyrosine hydroxylase, calbindin and substance P in the human midbrain and substantia nigra in relation to nigrostriatal projections and differential neuronal susceptibility in Parkinson's disease. Brain Res 1992;581:283-291
12. Swartz HM, Sarna T, Zecca L. Modulation by neuromelanin of the availability and reactivity of metal ions. Ann Neurol 1992;32(Suppl.): S69-S75
13. Enochs WS, Sarna T, Zecca L, Riley PA, Swartz HM. The roles of neuromelanin, binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson's disease: a hypothesis. J Neural Transm Park Dis Dement Sect 1994;7:83-100
14. Zecca L, Zucca FA, Wilms H, Sulzer D. Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. Trends Neurosci 2003;26:578-580
15. Wilms H, Rosenstiel P, Sievers J, Deuschl G, Zecca L, Lucius R. Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease. FASEB J 2003;17:500-502
16. Barden H. The histochemical relationships and nature of neuromelanin. In: Brody H, Harman D, Ordy JM, eds. Central Nervous System. New York: Raven Press; 1975, pp. 79-117
17. van Woert MH, Ambani LM. Biochemistry of neuromelanin. Adv Neurol 1974;5:215-223
18. Enochs WS, Nilges MJ, Swartz HM. Purified human neuromelanin, synthetic dopamine melanin as a potential model pigment, and the normal human substantia nigra: characterization by electron paramagnetic resonance spectroscopy. J Neurochem 1993;61:68-79
19. Zecca L, Swartz HM. Total and paramagnetic metals in human substantia nigra and its neuromelanin. J Neural Transm Park Dis Dement Sect 1993;5:203-213
20. Zecca L, Pietra R, Goj C, Mecacci C, Radice D, Sabbioni E. Iron and other metals in neuromelanin, substantia nigra, and putamen of human brain. J Neurochem 1994;62:1097-1101
21. Zecca L, Shima T, Stroppolo A, Goj C, Battiston GA, Gerbasi R, Sarna T, Swartz HM. Interaction of neuromelanin and iron in substantia nigra and other areas of human brain. Neuroscience 1996;73:407-415
22. Carstam R, Brinck C, Hindemith-Augustsson A, Rorsman H, Rosengren E. The neuromelanin of the human substantia nigra. Biochim Biophys Acta 1991;1097:152-160
23. Ito S, Wakamatsu K. Chemical degradation of melanins: application to identification of dopamine-melanin. Pigment Cell Res 1998;11:120-126
24. Odh G, Carstam R, Paulson J, Wittbjer A, Rosengren E, Rorsman H. Neuromelanin of the human substantia nigra: a mixed-type melanin. J Neurochem 1994;62:2030-2036
25. Zecca L, Mecacci C, Seraglia R, Parati E. The chemical characterization of melanin contained in substantia nigra of human brain. Biochim Biophys Acta 1992;1138:6-10
26. Bridelli MG, Tampellini D, Zecca L. The structure of neuromelanin and its iron binding site studied by infrared spectroscopy. FEBS Lett 1999;457:18-22
27. Double KL, Zecca L, Costi P, Mauer M, Griesinger C, Ito S, Ben-Shachar D, Bringmann G, Fariello RG, Riederer P, Gerlach M. Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melanins. J Neurochem 2000;75:2583-2589
28. Dzierzega-Lecznar A, Kurkiewicz S, Stepien K, Chodurek E, Wilczok T, Arzberger T, Riederer P, Gerlach M. GC/MS analysis of thermally degraded neuromelanin from the human substantia nigra. J Am Soc Mass Spectrom 2004;15:920-926
29. Zecca L, Costi P, Mecacci C, Ito S, Terreni M, Sonnino S. Interaction of human substantia nigra neuromelanin with lipids and peptides. J Neurochem 2000;74:1758-1765
30. Wakamatsu K, Fujikawa K, Zucca FA, Zecca L, Ito S. The structure of neuromelanin as studied by chemical degradative methods. J Neurochem 2003;86:1015-1023
31. Sulzer D, Bogulavsky J, Larsen KE, Behr G, Karatekin E, Kleinman MH, Turro N, Krantz D, Edwards RH, Greene LA, Zecca L. Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc Natl Acad Sci U S A 2000;97:11869-11874
32. Cheng J, Moss SC, Eisner M. X-ray characterization of melanins-II. Pigment Cell Res 1994;7:263-273
33. Crippa R, Wang QJ, Eisner M, Moss SC, Zecca L, Zschack P, Gog T. Structure of Human Neuromelanin by X-ray Diffraction: Comparison with Synthetics. Abstract, Anaheim: XVIth Internat Pigment Cell Conference; 1996
34. Xu Y, Stokes AH, Freeman WM, Kumer SC, Vogt BA, Vrana KE. Tyrosinase mRNA is expressed in human substantia nigra. Brain Res Mol Brain Res 1997;45:159-162
35. Tief K, Schmidt A, Beermann F. New evidence for presence of tyrosinase in substantia nigra, forebrain and midbrain. Brain Res Mol Brain Res 1998;53:307-310
36. Cooksey CJ, Garratt PJ, Land EJ, Pavel S, Ramsden CA, Riley PA, Smit NP. Evidence of the indirect formation of the catecholic intermediate substrate responsible for the autoactivation kinetics of tyrosinase. J Biol Chem 1997;272:26226-26235
37. Ikemoto K, Nagatsu I, Ito S, King RA, Nishimura A, Nagatsu T. Does tyrosinase exist in neuromelanin-pigmented neurons in the human substantia nigra? Neurosci Lett 1998;253:198-200
38. Foley JM, Baxter D. On the nature of pigment granules in the cell of the locus coeruleus and substantia nigra. J Neuropathol Exp Neurol 1958;17:586-598
39. Haavik J. L-DOPA is a substrate for tyrosine hydroxylase. J Neurochem 1997;69:1720-1728
40. Okun MR. The role of peroxidase in neuromelanin synthesis: a review. Physiol Chem Phys Med NMR 1997;29:15-22
41. Mattammal MB, Strong R, Lakshmi VM, Chung HD, Stephenson AH. Prostaglandin H synthetase-mediated metabolism of dopamine: implication for Parkinson's disease. J Neurochem 1995;64:1645-1654
42. Hastings TG. Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J Neurochem 1995;64:919-924
43. Matsunaga J, Sinha D, Pannell L, Santis C, Solano F, Wistow GJ, Hearing VJ. Enzyme activity of macrophage migration inhibitory factor toward oxidized catecholamines. J Biol Chem 1999;274:3268-3271
44. Fornstedt B, Rosengren E, Carlsson A. Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species. Neuropharmacology 1986;25:451-454
45. Liu Y, Edwards RH. The role of vesicular transport proteins in synaptic transmission and neural degeneration. Annu Rev Neurosci 1997;20:125-156
46. Solano F, Hearing VJ, Garcia-Borron JC. Neurotoxicity due to o-quinones: neuromelanin formation and possible mechanisms for o-quinone detoxification. Neurotox Res 2000;1:153-169
47. Liang CL, Nelson O, Yazdani U, Pasbakhsh P, German DC. Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter-2: human midbrain dopamine neurons. J Comp Neurol 2004;473:97-106
48. Langsten JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-980
49. Langsten JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 1999;46:598-605
50. Langsten JW, Irwin I. MPTP: current concepts and controversies. Clin Neuropharmacol 1986;9:485-507
51. Gerlach M, Riederer P. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 1996;103:987-1041
52. Langsten JW, Forno LS, Rebert CS, Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res 1984;292:390-394
53. Langsten JW, Irwin I, Langsten EB, Forno LS. 1-Methyl-4-phenylpyridinium ion (MPP +): identification of a metabolite of MPTP, a toxin selective to the substantia nigra. Neurosci Lett 1984;48:87-92
54. Markey SP, Johannessen JN, Chiueh CC, Burns RS, Herkenham MA. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 1984;311:464-467
55. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003;39:889-909
56. Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 1985;82:2173-2177
57. Singer TP, Castagnoli N Jr, Ramsay RR, Trevor AJ. Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine. J Neurochem 1987;49:1-8
58. Adams JD Jr, Odunze IN. Biochemical mechanisms of 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine toxicity. Could oxidative stress be involved in the brain? Biochem Pharmacol 1991;41:1099-1105
59. Nicklas WJ, Vyas I, Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci 1985;36:2503-2508
60. D'Amato RJ, Lipman ZP, Snyder SH. Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin. Science 1986;231:987-989
61. Ostergren A, Annas A, Skog K, Lindquist NG, Brittebo EB. Longterm retention of neurotoxic beta-carbolines in brain neuromelanin. J Neural Transm 2004;111:141-157
62. Lindquist NG, Larsson BS, Lyden-Sokolowski A. Autoradiography of [14C]paraquat or [14C]diquat in frogs and mice: accumulation in neuromelanin. Neurosci Lett 1988;93:1-6
63. Salazar M, Sokoloski TD, Patil PN. Binding of dopaminergic drugs by the neuromelanin of the substantia nigra, synthetic melanins and melanin granules. Fed Proc 1978;37:2403-2407
64. Aime S, Fasano M, Bergamasco B, Lopiano L, Valente G. Evidence for a glycidic-lipidic matrix in human neuromelanin, potentially responsible for the enhanced iron sequestering ability of substantia nigra. J Neurochem 1994;62:369-371
65. Barden H. The histochemical relationship of neuromelanin and lipofuscin. J Neuropathol Exp Neurol 1969;28:419-441
66. Gerlach M, Trautwein AX, Zecca L, Youdim MBH, Riederer P. Mossbauer spectroscopic studies of purified human neuromelanin isolated from the substantia nigra. J Neurochem 1995;65:923-926
67. Zecca L, Tampellini D, Gatti A, Crippa R, Eisner M, Sulzer D, Ito S, Fariello R, Gallorini M. The neuromelanin of human substantia nigra and its interaction with metals. J Neural Transm 2002;109:663-672
68. Moos T. Absence of ferritin protein in substantia nigra pars compacta neurons. A reappraisal to the role of iron in Parkinson's disease pathogenesis. Mov Disord 2000;15(Suppl. 3):319A
69. Zareba M, Bober A, Korytowski W, Zecca L, Sarna T. The effect of a synthetic neuromelanin on yield of free hydroxyl radicals generated in model systems. Biochim Biophys Acta 1995;1271:343-348
70. Double KL, Gerlach M, Schunemann V, Trautwein AX, Zecca L, Gallorini M, Youdim MB, Riederer P, Ben-Shachar D. Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem Pharmacol 2003:66:489-494
71. Liu Y, Hong L, Kempf VR, Wakamatsu K, Ito S, Simon JD. Ion-exchange and adsorption of Fe(III) by Sepia melanin. Pigment Cell Res 2004;17:262-269
72. Galazka-Friedman J, Bauminger ER, Friedman A, Barcikowska M, Hechel D, Nowik I. Iron in parkinsonian and control substantia nigra - a Mossbauer spectroscopy study. Mov Disord 1996;11:8-16
73. Lopiano L, Chiesa M, Digilio G, Giraudo S, Bergamasco B, Torre E, Fasano M. Q-band EPR investigations of neuromelanin in control and Parkinson's disease patients. Biochim Biophys Acta 2000;1500:306-312
74. Zecca L, Gallorini M, Schunemann V, Trautwein AX, Gerlach M, Riederer P, Vezzoni P, Tampellini D. Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J Neurochem 2001;76:1766-1773
75. Jellinger K, Kienzl E, Rumpelmair G, Riederer P, Stachelberger H, Ben-Shachar D, Youdim MBH. Iron-melanin complex in substantia nigra of parkinsonian brains: an X-ray microanalysis. J Neurochem 1992;59:1168-1171
76. Perl DP, Good PF. Comparative technques for determining cellular iron distribution in brain tissues. Ann Neurol 1992;32(Suppl.):S76-S81
77. Faucheux BA, Martin ME, Beaumont C, Hauw JJ, Agid Y, Hirsch EC. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. J Neurochem 2003;86:1142-1148
78. Ben-Shachar D, Riederer P, Youdim MB. Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J Neurochem 1991;57:1609-1614
79. Shima T, Sarna T, Swartz HM, Stroppolo A, Gerbasi R, Zecca L. Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: an electron paramagnetic resonance spectroscopy study. Free Radic Biol Med 1997;23:110-119
80. Kropf AJ, Bunker BA, Eisner M, Moss SC, Zecca L, Stroppolo A, Crippa PR. X-ray absorption fine-structure spectroscopy studies of Fe sites in natural human neuromelanin and synthetic analogues. Biophys J 1998;75:3135-3142
81. Cotzias GC, Papavasiliou PS, Van Woert MH, Sakamoto A. Melanogenesis and extrapiramidal diseases. Fed Proc 1964;23:713-718
82. Bazelon M, Fenichel GM, Randall J. Studies on neuromelanin. 1. A melanin system in the human adult brainstem. Neurology 1967;17:512-519
83. Mann DM, Yates PO. Lipoprotein pigments - their relationship to ageing in the human nervous system. II. The melanin content of pigmented nerve cells. Brain 1974;97:489-498
84. Bogerts B. A brainstem atlas of catecholaminergic neurons in man, using melanin as a natural marker. J Comp Neurol 1981;197:63-80
85. Cowen D. The melanoneurons of the human cerebellum (nucleus pigmentosus cerebellaris) and homologues in the monkey. J Neuropathol Exp Neurol 1986;45:205-221
86. McGeer PL, McGeer EG, Suzuki JS. Aging and extrapyramidal function. Arch Neurol 1977;34:33-35
87. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301
88. Pakkenberg B, Moller A, Gundersen HJ, Mouritzen Dam A, Pakkenberg H. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiatry 1991;54:30-33
89. Muthane U, Yasha TC, Shankar SK. Low numbers and no loss of melanized nigral neurons with increasing age in normal human brains from India. Ann Neurol 1998;43:283-287
90. Kubis N, Faucheux BA, Ransmayr G, Damier P, Duyckaerts C, Henin D, Forette B, Le Charpentier Y, Hauw JJ, Agid Y, Hirsch EC. Preservation of midbrain catecholaminergic neurons in very old human subjects. Brain 2000;123:366-373
91. Gibb WR, Lees AJ. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry 1991;54:388-396
92. Mann DM, Yates PO. Possible role of neuromelanin in the pathogenesis of Parkinson's disease. Mech Ageing Dev 1983;21:193-203
93. Offen D, Ziv I, Barzilai A, Gorodin S, Glater E, Hochman A, Melamed E. Dopamine-melanin induces apoptosis in PC12 cells; possible implications for the etiology of Parkinson's disease. Neurochem Int 1997;31:207-216
94. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988;38:1285-1291
95. Hunot S, Hirsch EC. Neuroinflammatory processes in Parkinson's disease. Ann Neurol 2003;53(Suppl. 3): S49-S58
96. Double KL, Ben-Shachar D, Youdim MB, Zecca L, Riederer P, Gerlach M. Influence of neuromelanin on oxidative pathways within the human substantia nigra. Neurotoxicol Teratol 2002;24:621-628